Advertisement Fidelity
Home > Boards > US OTC > Medical - Drugs >

Advanced Cell Technology (ACTC)

ACTC RSS Feed
Add ACTC Price Alert      Hide Sticky   Hide Intro
Moderator: No Moderator locksflooring, sports guy, Kapla, LODE MAKING ME RICH, homeslice10, lasers
Search This Board:
Last Post: 4/19/2014 12:45:12 PM - Followers: 599 - Board type: Free - Posts Today: 7

 
Advanced Cell Technology, Inc. (ACTC)

 

 

http://www.advancedcell.com

 

 

 

Company Headquarters:

Advanced Cell Technology, Inc.
P.O. Box 1700
Santa Monica, CA 90406

Tel: (310) 576 0611
Fax: (310) 576 0662

info@advancedcell.com

 

Massachusetts Laboratory Facility
33 Locke Dr.
Marlborough, MA 01752
Tel: (508) 756-1212
Fax: (508) 229-2333


THE COMPANY:
 

Advanced Cell Technology, Inc. ("ACT"; OTCBB: ACTC) is a biotechnology company developing cellular therapies for the treatment of diseases that impact millions of people worldwide. The company is currently conducting the only ongoing, FDA-cleared human embryonic stem cell (hESC)-based human clinical trials. The two trials, initiated in July 2011 at UCLA's Jules Stein Eye Institute, use retinal pigment epithelial (RPE) cells derived from hESCs to treat forms of macular degeneration. ACT also recently received approval from the UK Medicines & Healthcare Products Regulatory Agency (MHRA) to conduct the first hESC trial in Europe. The company is also developing its Hemangioblast (HG) platform for the treatment of blood and cardiovascular diseases, its Phase II-cleared Myoblast stem cell therapy for the treatment of chronic heart failure and other cardiac conditions, and other programs.

ACT's principal laboratory and GMP facility is in Marlborough, Massachusetts, and its corporate offices are in Santa Monica, California. ACT is led by an experienced management team and a world-class scientific team helmed, respectively, by interim chairman and CEO Gary Rabin and chief scientific officer Robert Lanza, M.D.


PATENTS & INTELLECTUAL PROPERTY (IP):

ACT owns or licenses more than 150 patents and patent applications related to stem cell therapy and regenerative medicine, and is positioning itself to have a dominant patent position around its stem cell-derived RPE program in leading markets around the world.
 
In 2010 ACT secured three far-reaching patents related to its RPE program, and more recently was issued the first patent for generating hemangioblast cells to treat a broad spectrum of vascular and hematopoietic disorders.
 
 
THERAPEUTIC PLATFORMS:

The company's RPE and HG programs are hESC-based, and its Myoblast program for cardiac disease is an adult autologous stem cell therapy. As documented in NATURE and Cell Stem Cell, ACT developed the "single-cell blastomere" technique, the first-ever proven alternative method for successful hESC generation without harm to the embryo, for which it was recently issued a broad patent
 
RPE Program - ACT has developed a fully-differentiated RPE cell derived from human embryonic stem cells, which can be used as a cellular therapy to treat retinal degenerative diseases. In July 2011 ACT initiated two Phase I/II clinical trials to test the safety of the therapy for Stargardt's Macular Dystrophy (SMD), and for Dry Age-Related Macular Degeneration (Dry AMD). Dry AMD represents a $25-30 Billion market in the US and Europe alone, and there are no approved therapies currently available for either condition. Two patients have thus far been treated at UCLA, Institutional Review Board (IRB) approval for the SMD clinical trial has also been issued by Oregon Health & Science University (OHSU) and European regulatory clearance has been granted to initiate the first hESC trial in Europe.
Other recent milestones in ACT's RPE program include: the NIH proposed expanding its definition of hESCs for funding purposes, in part to accommodate ACT's lines derived using its patented "embryo-safe" single-cell blastomere technique; and both the FDA and the European Medicines Agency (EMA) granting ACT's RPE cells "Orphan" status for treatment of Stargardt's Disease.
 
Hemangioblast Program - ACT's Hemangioblast program is for the treatment of blood and cardiovascular diseases. A paper published in NATURE Methods revealed the company's successful generation of functional Hemangioblast cells from human embryonic stem cells, and a paper published earlier this year in Cell Research indicated that hESCs could be a potentially unlimited source of platelets for transfusion.
 
Myoblast Program - ACT's Myoblast treatment may prove particularly beneficial for patients who have experienced a serious heart attack and are at risk for heart failure. ACT has secured FDA approval to commence with Phase II clinical trials. The Myoblast program has several advantages over currently-available approaches, including symptom management and disease modification.



Dr. Lanza explains some of the technology we are pursuing: http://www.youtube.com/watch?v=MPBiNlUFIww#t=55s


For more information visit www.AdvancedCell.com


Filings:

http://www.sec.gov/cgi-bin/browse-edgar?company=&match=&CIK=0001140098&filenum=&State=&Country=&SIC=&owner=exclude&Find=Find+Companies&action=getcompany

 

Share Structure as of November 30, 2011:
 

Outstanding Shares
1,705,673,605

Reserved Shares
124,827,644

Authorized and Unreserved Shares

919,498,751

 

Authorized Preferred Shares

50,000,000

 

The following table sets forth information regarding beneficial ownership of our capital stock as of November 30, 2011 by:

·  5% or greater stockholders;
·  Each of our directors and named executive officers; and
·  All of our directors and executive officers, as a group.

 

Name and Address (1) of Beneficial Owner                                                                                         Common Stock Beneficially Owned                   Percentage of Shares Beneficially Owned 
5% or Greater Stockholders
None
Directors and Named Executive Officers
William M. Caldwell, IV**                                                                                                                             95,415,141 (1)                                                           5.58%%

Robert P. Lanza, M.D.                                                                                                                                  51,199,082 (2)                                                           2.97%%

Alan C. Shapiro                                                                                                                                           20,150,927 (3)                                                           1.18%%
Erkki Ruoslahti                                                                                                                                            2,500,000 (4)                                                                *
Gary Rabin                                                                                                                                                 23,087,430 (5)                                                           1.35%
Directors and Executive Officers as a Group (5 Persons)                                                                                192,352,580                                                               11.08%%

                                                                     

* Less than 1%

** Mr. Caldwell passed away on December 13, 2010

(1) Includes 5,108,546 shares subject to stock options that are currently exercisable or exercisable within 60 days of November 30, 2011.

(2) Includes 17,583,207 shares subject to stock options that are currently exercisable or exercisable within 60 days of November 30, 2011.

(3) Includes (i) 17,032,587 shares subject to convertible debentures, board fees, common stock grant held by The Shapiro Family Trust and of
which Dr. Shapiro may be deemed the beneficial owner, (ii) 3,018,340 shares subject to warrants in connection with the 2005-2008
convertible debentures, and (iii) 100,000 shares subject to stock options that are currently exercisable or exercisable within 60 days of
November 30, 2011.

(4) Includes 100,000 shares issuable upon exercise of options exercisable within 60 days of November 30, 2011. Effective August 1, 2011,
Erkki Ruoslahti resigned from the Board of Directors of the Company.

(5) Includes indirect ownership of (i) 1,239,501 shares issued to PDPI, LLC on December 22, 2010, upon exercise of certain warrants, which
such number of shares represents Mr. Rabin's proportional interest in the total number of shares held by PDPI, LLC, based on his 33.33%
equity interest in the entity. Mr. Rabin disclaims beneficial ownership in the shares held by PDPI, LLC, and (ii) 7,000,000 shares subject
to stock options that are currently exercisable or exercisable within 60 days of November 30, 2011.

There are no arrangements known to the Company, including any pledge by any person of securities of the Company, the operation of
which may at a subsequent date result in a change in control of the Company.
 

Media Relations

Bill Douglass
Gotham Communications, LLC
(646)450-3615
bill [at] gothamcomm [dot] com

or

Martina Schwarzkopf, Ph.D.
Russo Partners, LLC
(212) 845-4292
martina.schwarzkopf [at] russopartnersllc [dot] com

Investor Relations

James Young
jyoung [at] ceocast [dot] com
(212) 732-4300

 

 

 

 

 


All messages, including iBox content, are the opinion of the posters, are no substitute for your own research, and should not be relied upon for stock trading or any other purpose.

 

 

 

Rules of the board according to IHUB:
http://www.investorshub.com/boards/complex_terms.asp

 

  • 1D
  • 1M
  • 2M
  • 3M
  • 6M
  • 1Y
  • 2Y
  • 3Y
  • 5Y
ACTC
Current Price
Volume:
Bid Ask Day's Range
Wiki
PostSubject
#64886   Advanced Cell Technology... ddls 04/19/14 12:45:12 PM
#64884   And it was on my Etrade pro level 2 Magicmike22 04/19/14 12:12:40 PM
#64883   Other then the 1m I don't remember the Magicmike22 04/19/14 11:41:54 AM
#64882   Magicmike22 - where did you see this 1m+ alteza 04/19/14 11:37:48 AM
#64880   'Magicmike22 Please buy away, and be my guest! ddls 04/19/14 01:44:59 AM
#64879   The 1m+ bid with CDEL made me buy Magicmike22 04/18/14 08:14:07 PM
#64878   I agree, the updates are pathetic around here. ddls 04/18/14 06:32:48 PM
#64877   Do you have an estimate on how much ddls 04/18/14 06:20:46 PM
#64876   GaryRabinsname needs to be erased be moderators above. chuckanutman 04/18/14 05:28:08 PM
#64875   Our focus is the companies advancement towards commercialization andyshow 04/18/14 04:43:02 PM
#64874   Why Yes! that's why the PPS has erupted ddls 04/18/14 04:37:13 PM
#64873   Rabin?? Don't dwell in the past... Follow us andyshow 04/18/14 04:03:29 PM
#64872   And all those BioTech conferences they attended...yielded nothing? ddls 04/18/14 03:43:32 PM
#64871   May I hang my dirty laundry on it? ddls 04/18/14 03:24:58 PM
#64870   Of course everyone knows that when this goes ddls 04/18/14 03:22:07 PM
#64867   Don't hang your hat on this but on elysse1kittycat 04/18/14 02:28:44 PM
#64865   Yes, I thank them for those short dollars ddls 04/18/14 01:47:33 PM
#64864   More like ACTC "Team Flatlined" thinking as in ddls 04/18/14 01:45:49 PM
#64863   $$$$$$$$$$ ACTC $$$$$$$$$$ beninsac 04/18/14 01:44:01 PM
#64862   ACTC Team "Medical Breakthrough" thinking green as-in-up. chuckanutman 04/18/14 01:17:52 PM
#64860   Advanced Cell Technology's Sales Staff Is Awesome! ddls 04/18/14 12:47:18 PM
#64859   thank you for this article, it is awesome! erik007tc 04/18/14 10:57:43 AM
#64858   Anyone that wants to know the history of Wopsal101 04/18/14 10:23:19 AM
#64857   Researchers Clone Cells From Two Adult Men ChopperMountain 04/18/14 09:12:40 AM
#64856   The Jason Lewis show spent an hour last ChopperMountain 04/18/14 08:51:02 AM
#64855   Glad to hear this, more info ahead for sure. chuckanutman 04/18/14 12:11:19 AM
#64854   "A new therapy and the first of its andyshow 04/18/14 12:08:19 AM
#64853   They said: The publications related to safety of chuckanutman 04/18/14 12:01:16 AM
#64852   I understand but it was positioned as if andyshow 04/17/14 11:48:08 PM
#64851   Shows ACTC has the game changing science. :) chuckanutman 04/17/14 11:46:30 PM
#64850   Can you guys please tell me what you andyshow 04/17/14 11:11:27 PM
#64849   Why did they drag their feed? If they Trader Joey 04/17/14 10:23:50 PM
#64848   ACTC has wonderfull-people that enjoy this unique opportunity. chuckanutman 04/17/14 09:35:36 PM
#64847   If that author has an email address embedded north40000 04/17/14 09:14:24 PM
#64846   via npr: First Embryonic Stem Cells Cloned From InVest14 04/17/14 09:13:22 PM
#64845   OT: HUMAN EMBRYONIC STEM CELLS – A SEVENTEEN-YEAR STALEMATE elllk 04/17/14 07:43:05 PM
#64843   I like Marc's response to this article. Fern Wood 04/17/14 04:17:09 PM
#64842   You can't rush good science. Look at homeslice10 04/17/14 04:16:47 PM
#64840   CISCO, may I suggest that what you're missing farviewhill 04/17/14 03:47:30 PM
#64838   Nice article which shows what is going to elysse1kittycat 04/17/14 03:10:19 PM
#64837   $40Bill Thxs. Post Often! lasers 04/17/14 02:53:33 PM
#64836   So many posibilities, ACT is a live performance chuckanutman 04/17/14 02:47:14 PM
#64835   Great D Lasers. Personmark 4 u :-) thanks $40Bill 04/17/14 02:26:42 PM
#64833   WSJ Scientists Make First Embryo Clones From Adults lasers 04/17/14 01:56:20 PM
#64832   I partially disagree, not from the investment point Cisco_Tajuara 04/17/14 01:51:57 PM
#64831   I've been adding to a position here for $40Bill 04/17/14 01:41:39 PM
#64830   The Calcutta India Telegraph Paper likes ACTC :) chuckanutman 04/17/14 01:25:00 PM
#64829   Gmayes, thanks for sharing. farviewhill 04/17/14 01:17:29 PM
#64828   Contrary to the volume you speak of... There andyshow 04/17/14 01:13:00 PM
#64827   They've dragged their feed in phase 1! 4 ddls 04/17/14 01:11:01 PM
PostSubject